BioNTech SE (BNTX) Stock Forecast & Price Target

Compare

4,649 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BNTX Analyst Ratings

Moderate Buy

14 Buy

5 Hold

0 Sell

Based on 19 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$140.06

▲(35.97% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $140.06 with a high forecast of $185.00 and a low forecast of $112.00. The average price target represents a 35.97% change from the last price of $103.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","186":"$186","105.75":"$105.8","132.5":"$132.5","159.25":"$159.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,105.75,132.5,159.25,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,113.31384615384616,119.28769230769231,125.26153846153846,131.23538461538462,137.20923076923077,143.18307692307692,149.15692307692308,155.13076923076923,161.10461538461539,167.07846153846154,173.0523076923077,179.02615384615385,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,109.85692307692308,112.37384615384616,114.89076923076924,117.40769230769232,119.9246153846154,122.44153846153847,124.95846153846153,127.47538461538463,129.9923076923077,132.50923076923078,135.02615384615385,137.54307692307694,{"y":140.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,107.69846153846154,108.05692307692308,108.41538461538462,108.77384615384615,109.13230769230769,109.49076923076923,109.84923076923077,110.20769230769231,110.56615384615385,110.92461538461538,111.28307692307692,111.64153846153846,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$185.00

Average Price Target$140.06

Lowest Price Target$112.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

$120

Hold

16.49%

Upside

Reiterated

08/27/25

BioNTech SE (BNTX) Receives a Hold from TD Cowen

Dex Genotek

TR | OpenAI - 4o

$115→$105

Hold

1.93%

Upside

Reiterated

08/26/25

AI Generated ArticleAI Generated Article

Terence Flynn

Morgan Stanley

$133

Buy

29.11%

Upside

Reiterated

08/25/25

Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)

Eliana Merle

UBS

$115

Hold

11.64%

Upside

Reiterated

08/22/25

UBS Remains a Hold on BioNTech SE (BNTX)

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Optimistic Buy Rating for BioNTech SE Amid Promising Pumitamig Trial Results

Robert Burns

H.C. Wainwright

$138→$136

Buy

32.03%

Upside

Reiterated

08/14/25

BioNTech price target lowered to $136 from $138 at H.C. WainwrightBioNTech price target lowered to $136 from $138 at H.C. Wainwright

Akash Tewari

Jefferies

$151

Buy

46.59%

Upside

Reiterated

08/05/25

Jefferies Remains a Buy on BioNTech SE (BNTX)

Emmanuel Papadakis

Deutsche Bank

$140

Buy

35.91%

Upside

Reiterated

08/05/25

BioNTech SE (BNTX) Receives a Buy from Deutsche Bank

Asthika Goonewardene

Truist Financial

$155

Buy

50.47%

Upside

Reiterated

08/05/25

Truist Financial Keeps Their Buy Rating on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

$125→$130

Buy

26.20%

Upside

Reiterated

08/04/25

BioNTech SE (BNTX) Gets a Buy from Evercore ISI

William Maughan

Clear Street

$181→$185

Buy

79.59%

Upside

Reiterated

08/04/25

BioNTech price target raised to $185 from $181 at Clear StreetBioNTech price target raised to $185 from $181 at Clear Street

Mohit Bansal

Wells Fargo

$170→$150

Buy

45.62%

Upside

Reiterated

08/04/25

BioNTech's Strategic Oncology Focus and Strong Financials Drive Buy Rating

Asad Haider

Goldman Sachs

$110→$112

Hold

8.73%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Ardent Health Partners, Inc. (NYSE: ARDT) and Henry Schein (NASDAQ: HSIC)

Tazeen Ahmad

Bank of America Securities

$126→$134

Buy

30.08%

Upside

Reiterated

08/04/25

BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation

Jessica Fye

J.P. Morgan

$116

Hold

12.61%

Upside

Reiterated

07/17/25

J.P. Morgan Sticks to Its Hold Rating for BioNTech SE (BNTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

$120

Hold

16.49%

Upside

Reiterated

08/27/25

BioNTech SE (BNTX) Receives a Hold from TD Cowen

Dex Genotek

TR | OpenAI - 4o

$115→$105

Hold

1.93%

Upside

Reiterated

08/26/25

AI Generated ArticleAI Generated Article

Terence Flynn

Morgan Stanley

$133

Buy

29.11%

Upside

Reiterated

08/25/25

Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)

Eliana Merle

UBS

$115

Hold

11.64%

Upside

Reiterated

08/22/25

UBS Remains a Hold on BioNTech SE (BNTX)

Daina Graybosch

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Optimistic Buy Rating for BioNTech SE Amid Promising Pumitamig Trial Results

Robert Burns

H.C. Wainwright

$138→$136

Buy

32.03%

Upside

Reiterated

08/14/25

BioNTech price target lowered to $136 from $138 at H.C. WainwrightBioNTech price target lowered to $136 from $138 at H.C. Wainwright

Akash Tewari

Jefferies

$151

Buy

46.59%

Upside

Reiterated

08/05/25

Jefferies Remains a Buy on BioNTech SE (BNTX)

Emmanuel Papadakis

Deutsche Bank

$140

Buy

35.91%

Upside

Reiterated

08/05/25

BioNTech SE (BNTX) Receives a Buy from Deutsche Bank

Asthika Goonewardene

Truist Financial

$155

Buy

50.47%

Upside

Reiterated

08/05/25

Truist Financial Keeps Their Buy Rating on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

$125→$130

Buy

26.20%

Upside

Reiterated

08/04/25

BioNTech SE (BNTX) Gets a Buy from Evercore ISI

William Maughan

Clear Street

$181→$185

Buy

79.59%

Upside

Reiterated

08/04/25

BioNTech price target raised to $185 from $181 at Clear StreetBioNTech price target raised to $185 from $181 at Clear Street

Mohit Bansal

Wells Fargo

$170→$150

Buy

45.62%

Upside

Reiterated

08/04/25

BioNTech's Strategic Oncology Focus and Strong Financials Drive Buy Rating

Asad Haider

Goldman Sachs

$110→$112

Hold

8.73%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Ardent Health Partners, Inc. (NYSE: ARDT) and Henry Schein (NASDAQ: HSIC)

Tazeen Ahmad

Bank of America Securities

$126→$134

Buy

30.08%

Upside

Reiterated

08/04/25

BioNTech SE: Strategic Growth and Innovation in Oncology Amidst Strong Financial Foundation

Jessica Fye

J.P. Morgan

$116

Hold

12.61%

Upside

Reiterated

07/17/25

J.P. Morgan Sticks to Its Hold Rating for BioNTech SE (BNTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month

xxx

Success Rate

14/24 ratings generated profit

Average Return

+1.82%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +1.82% per trade.

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+1.16%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.16% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

16/24 ratings generated profit

Average Return

+0.56%

reiterated a buy rating 25 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +0.56% per trade.

2 Years

xxx

Success Rate

18/24 ratings generated profit

Average Return

+5.20%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +5.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BNTX has received 40 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 140.06.

Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$1.22 with a range of -$2.46 to $0.84. The previous quarter’s EPS was -$1.87. BNTX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $791.87M with a range of $459.20M to $1.14B. The previous quarter’s sales results were $295.83M. BNTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 140.06.

What is BNTX’s upside potential, based on the analysts’ average price target?

BioNTech SE has 35.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BNTX a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioNTech SE’s price target?

The average price target for BioNTech SE is 140.06. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $112.00. The average price target represents 35.97% Increase from the current price of $103.01.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of BNTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioNTech SE (BNTX) Stock Forecast & Price Target

BNTX Analyst Ratings

BNTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

BNTX Analyst Recommendation Trends

BNTX Financial Forecast

BNTX Earnings Forecast

BNTX Sales Forecast

BNTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts